BiovaxID(R) Lymphoma Vaccine-Induced T-Cell Immune Responses Complement …MarketWatch (press release)The results (detailed in Abstract #2707), reported by a Senior Investigator from the NCI, demonstrated that vaccination with BiovaxID active immunothe…
Roche's blood cancer antibody outperforms MabTheraPMLiVERoche says it will now press on with phase III testing of GA101 as an alternative to MabThera (rituximab), which was originated by Biogen Idec and is sold by Roche outside the USA and Japan. T…
Obinutuzumab: New Drug to Replace Rituximab?MedscapeDecember 12, 2011 (San Diego, California) — For more than a decade now, rituximab (Rituxan, Genentech) has reigned supreme as the only drug of its kind — a monoclonal antibody specifically targeti…
Benefit of Romiplostim vs. Standard of Care (SOC) and SOC+Rituximab in …Monthly Prescribing ReferenceEleven of 16 patients in the SOC arm received rituximab 219–363mg/m 2 once weekly for four weeks. In this post hoc, non-randomized comparison, inve…
Effective Response Rates of Lenalidomide and Rituximab as Initial Treatment of …Monthly Prescribing ReferenceSAN DIEGO, CA—Investigators at the 53 rd American Society of Hematology Annual Meeting and Exposition presented study data demonstrating hi…
Immunomedics Says SC Veltuzumab Produced High Response Rate In Relapsed ITPNASDAQResponses occurred across all doses tested, including the lowest dose at 80 mg, regardless of the route of administration, history of splenectomy or prior use of rituximab…
Fractionated 90 Y-Ibritumomab Tiuxetan Effective as First-Line Therapy for …Monthly Prescribing ReferencePatients with >20% bone marrow (BM) involvement received fractionated RIT only if a repeat BM biopsy demonstrated a reduction to ≤20% involv…
Excellent PFS and OS Observed with CHOP Combination Regimens in Newly …Monthly Prescribing ReferenceThe CHOP-R arm of patients received six cycles of CHOP chemotherapy (cyclophosphamide 750mg/m 2 , doxorubicin 50mg/m 2 , vincristine 1.4mg/m 2 , and p…
The Oncology ReportRe-treatment strategy challenges maintenance therapy for rituximab use in low …HemOncTodaySAN DIEGO — Patients with low tumor burden follicular lymphoma who received a maintenance dose of rituximab every 3 months did not have a l…
Impressive ZEVALIN® Data Highlighted at 53rd Annual Meeting of the American …TradersHuddle.com (press release)The authors have previously demonstrated that R-FND (rituximab, fludarabine, mitoxantrone, and dexamethasone) is an effective regimen for i…